Constitutive Interferon-Inducible Protein 16-Inflammasome Activation during Epstein-Barr Virus Latency I, II, and III in B and Epithelial Cells

被引:166
|
作者
Ansari, Mairaj Ahmed [1 ]
Singh, Vivek Vikram [1 ]
Dutta, Sujoy [1 ]
Veettil, Mohanan Valiya [1 ]
Dutta, Dipanjan [1 ]
Chikoti, Leela [1 ]
Lu, Jie [2 ,3 ]
Everly, David [1 ]
Chandran, Bala [1 ]
机构
[1] Rosalind Franklin Univ Med & Sci, HM Bligh Canc Res Labs, Dept Microbiol & Immunol, Chicago Med Sch, N Chicago, IL USA
[2] Univ Penn, Dept Microbiol, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Tumor Virol Program, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
INNATE IMMUNE SENSOR; DNA-DAMAGE RESPONSE; IFI16; INFLAMMASOME; INFECTION; BINDING; AUTOANTIGEN; INHIBITION; EXPRESSION; APOPTOSIS;
D O I
10.1128/JVI.00805-13
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Epstein-Barr virus (EBV), etiologically linked with human B-cell malignancies and nasopharyngeal carcinoma (NPC), establishes three types of latency that facilitate its episomal genome persistence and evasion of host immune responses. The innate inflammasome responses recognize the pathogen-associated molecular patterns which lead into the association of a cytoplasmic sensor such as NLRP3 and AIM2 proteins or nuclear interferon-inducible protein 16 (IFI16) with adaptor ASC protein (apoptosis-associated speck-like protein with a caspase recruitment domain) and effector procaspase-1, resulting in active caspase-1 formation which cleaves the proforms of inflammatory interleukin-1 beta (IL-1 beta), IL-18, and IL-33 cytokines. Whether inflammasome responses recognize and respond to EBV genome in the nuclei was not known. We observed evidence of inflammasome activation, such as the activation of caspase-1 and cleavage of pro-IL-1 beta, -IL-18, and -IL-33, in EBV latency I Raji cells, latency II NPC C666-1 cells, and latency III lymphoblastoid cell lines (LCL). Interaction between ASC with IFI16 but not with AIM2 or NLRP3 was detected in all three latencies and during EBV infection of primary human B cells. IFI16 and cleaved caspase-1, IL-1 beta, IL-18, and IL-33 were detected in the exosomes from Raji cells and LCL. Though EBV nuclear antigen 1 (EBNA1) and EBV-encoded small RNAs (EBERs) are common to all forms of EBV latency, caspase-1 cleavage was not detected in cells expressing EBNA1 alone, and blocking EBER transcription did not inhibit caspase-1 cleavage. In fluorescence in situ hybridization (FISH) analysis, IFI16 colocalized with the EBV genome in LCL and Raji cell nuclei. These studies demonstrated that constant sensing of latent EBV genome by IFI16 in all types of latency results in the constitutive induction of the inflammasome and IL-1 beta, IL-18, and IL-33 maturation.
引用
收藏
页码:8606 / 8623
页数:18
相关论文
共 43 条
  • [31] COMPARATIVE-ANALYSIS OF THE REGULATION OF THE INTERFERON-INDUCIBLE PROTEIN-KINASE PKR BY EPSTEIN-BARR-VIRUS RNAS EBER-1 AND EBER-2 AND ADENOVIRUS VA(I) RNA
    SHARP, TV
    SCHWEMMLE, M
    JEFFREY, I
    LAING, K
    MELLOR, H
    PROUD, CG
    HILSE, K
    CLEMENS, MJ
    NUCLEIC ACIDS RESEARCH, 1993, 21 (19) : 4483 - 4490
  • [32] Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells
    Rechsteiner, Markus P.
    Berger, Christoph
    Weber, Matthias
    Sigrist, Jurg A.
    Nadal, David
    Bernasconi, Michele
    JOURNAL OF GENERAL VIROLOGY, 2007, 88 : 1454 - 1459
  • [33] Latent membrane protein 1 regulates STAT1 through NF-κB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells
    Najjar, I
    Baran-Marszak, F
    Le Clorennec, C
    Laguillier, C
    Schischmanoff, O
    Youlyouz-Marfak, L
    Schlee, M
    Bornkamm, GW
    Raphaël, M
    Feuillard, J
    Fagard, R
    JOURNAL OF VIROLOGY, 2005, 79 (08) : 4936 - 4943
  • [34] Expression of the Epstein-Barr virus latent membrane protein 1 in human umbilical vein endothelial cells leads to NF-κB activation and protection from apoptosis
    Xiong, AM
    Valenzuela, GA
    Millan, MT
    FASEB JOURNAL, 2002, 16 (04): : A210 - A210
  • [35] Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells:: induction via NF-κB activation mediated by EBV-derived latent membrane protein 1
    Thompson, MP
    Aggarwal, BB
    Shishodia, S
    Estrov, Z
    Kurzrock, R
    LEUKEMIA, 2003, 17 (11) : 2196 - 2201
  • [36] The Epstein-Barr virus nuclear antigen 2 (EBNA2), a protein required for B lymphocyte immortalization, induces the synthesis of type I interferon in Burkitt's lymphoma cell lines
    Kanda, K
    Kempkes, B
    Bornkamm, GW
    von Gabain, A
    Decker, T
    BIOLOGICAL CHEMISTRY, 1999, 380 (02) : 213 - 221
  • [37] Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Impairs G2 Checkpoint in Human Nasopharyngeal Epithelial Cells through Defective Chk1 Activation
    Deng, Wen
    Pang, Pei Shin
    Tsang, Chi Man
    Hau, Pok Man
    Yip, Yim Ling
    Cheung, Annie L. M.
    Tsao, Sai Wah
    PLOS ONE, 2012, 7 (06):
  • [38] Surexpression of Epstein-Barr LMP1 protein in B lymphocytes infected by EBV in latency III resulting in auto-activation of CD95 independatly of its ligand and caspase 8 apoptosis dependant
    Le Clorennec, C.
    Ouk, T. S.
    Jayat-Vignoles, C.
    Youlyouz-Marfak, I
    Adriaenssens, E.
    Coll, J.
    Bornkamm, G. W.
    Feuillard, J.
    BULLETIN DU CANCER, 2007, 94 (06) : 539 - 539
  • [39] Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis c virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4+ T cells
    Chen, M
    Shirai, M
    Liu, ZJ
    Arichi, T
    Takahashi, H
    Nishioka, M
    JOURNAL OF VIROLOGY, 1998, 72 (10) : 8301 - 8308
  • [40] MECHANISMS OF B-CELL ACTIVATION IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME AND RELATED DISORDERS - CONTRIBUTION OF ANTIBODY-PRODUCING B-CELLS, OF EPSTEIN-BARR VIRUS-INFECTED B-CELLS, AND OF IMMUNOGLOBULIN PRODUCTION INDUCED BY HUMAN T-CELL LYMPHOTROPIC VIRUS, "TYPE-III/LYMPHADENOPATHY-ASSOCIATED VIRUS
    YARCHOAN, R
    REDFIELD, RR
    BRODER, S
    JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (02): : 439 - 447